The FDA has approved Wyeth's Tygacil antibiotic as the first in a new
class of drugs, this one for hospital infections that often defy
treatment. The intravenous drug is considered a
broad-spectrum antibiotic, which Wyeth said can be used as a first-line
therapy for staph and similar infections and is equivalent to some
current two-drug combinations.